1049 related articles for article (PubMed ID: 27085692)
1. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
Hofmann L; Forschner A; Loquai C; Goldinger SM; Zimmer L; Ugurel S; Schmidgen MI; Gutzmer R; Utikal JS; Göppner D; Hassel JC; Meier F; Tietze JK; Thomas I; Weishaupt C; Leverkus M; Wahl R; Dietrich U; Garbe C; Kirchberger MC; Eigentler T; Berking C; Gesierich A; Krackhardt AM; Schadendorf D; Schuler G; Dummer R; Heinzerling LM
Eur J Cancer; 2016 Jun; 60():190-209. PubMed ID: 27085692
[TBL] [Abstract][Full Text] [Related]
2. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.
Zimmer L; Goldinger SM; Hofmann L; Loquai C; Ugurel S; Thomas I; Schmidgen MI; Gutzmer R; Utikal JS; Göppner D; Hassel JC; Meier F; Tietze JK; Forschner A; Weishaupt C; Leverkus M; Wahl R; Dietrich U; Garbe C; Kirchberger MC; Eigentler T; Berking C; Gesierich A; Krackhardt AM; Schadendorf D; Schuler G; Dummer R; Heinzerling LM
Eur J Cancer; 2016 Jun; 60():210-25. PubMed ID: 27084345
[TBL] [Abstract][Full Text] [Related]
3. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
4. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
5. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
6. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
[TBL] [Abstract][Full Text] [Related]
7. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
Cancer Treat Rev; 2017 Jul; 58():70-76. PubMed ID: 28689073
[TBL] [Abstract][Full Text] [Related]
8. Novel melanoma therapies and their side effects.
González N; Ratner D
Cutis; 2016 Jun; 97(6):426-8. PubMed ID: 27416087
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
Menzies AM; Johnson DB; Ramanujam S; Atkinson VG; Wong ANM; Park JJ; McQuade JL; Shoushtari AN; Tsai KK; Eroglu Z; Klein O; Hassel JC; Sosman JA; Guminski A; Sullivan RJ; Ribas A; Carlino MS; Davies MA; Sandhu SK; Long GV
Ann Oncol; 2017 Feb; 28(2):368-376. PubMed ID: 27687304
[TBL] [Abstract][Full Text] [Related]
10. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
14. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A
Lancet; 2014 Sep; 384(9948):1109-17. PubMed ID: 25034862
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
[TBL] [Abstract][Full Text] [Related]
18. Managing immune checkpoint-blocking antibody side effects.
Postow MA
Am Soc Clin Oncol Educ Book; 2015; ():76-83. PubMed ID: 25993145
[TBL] [Abstract][Full Text] [Related]
19. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.
Ryder M; Callahan M; Postow MA; Wolchok J; Fagin JA
Endocr Relat Cancer; 2014 Apr; 21(2):371-81. PubMed ID: 24610577
[TBL] [Abstract][Full Text] [Related]
20. [A review of adverse events caused by immune checkpoint inhibitors].
Fukushima S
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(1):30-6. PubMed ID: 27181232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]